Rick Doblin, Ph.D., is the Founder in 1986 and President of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit that wholly owns its pharmaceutical arm, MAPS Public Benefit Corporation (PBC), which has completed two highly successful Phase 3 studies of MDMA-assisted therapy for PTSD. MAPS PBC stands at a crossroads between obtaining the additional resources it needs from philanthropy, ensuring public benefit is foremost, or becoming a publicly traded company.
